[go: up one dir, main page]

PE20190452A1 - Derivado de triazolopirazinona util como un inhibidor de pde1 humana - Google Patents

Derivado de triazolopirazinona util como un inhibidor de pde1 humana

Info

Publication number
PE20190452A1
PE20190452A1 PE2019000371A PE2019000371A PE20190452A1 PE 20190452 A1 PE20190452 A1 PE 20190452A1 PE 2019000371 A PE2019000371 A PE 2019000371A PE 2019000371 A PE2019000371 A PE 2019000371A PE 20190452 A1 PE20190452 A1 PE 20190452A1
Authority
PE
Peru
Prior art keywords
inhibitor
derivative useful
pde1
triazolopyrazinone
formula
Prior art date
Application number
PE2019000371A
Other languages
English (en)
Inventor
Mark David Rekhter
Qing Shi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20190452A1 publication Critical patent/PE20190452A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a un compuesto de Formula I: o una sal farmaceuticamente aceptable del mismo, que puede formar parte de una composicion farmaceutica junto a uno o mas diluyentes, portadores o excipientes farmaceuticamente aceptables. Tambien se refiere a metodos de preparacion de compuestos de la formula y composiciones farmaceuticas, y de tratamiento. La presente invencion es util como inhibidor de fosfodiesterasa 1 (PDE1) para el tratamiento de la enfermedad renal diabetica producto de la diabetes.
PE2019000371A 2016-08-25 2017-08-18 Derivado de triazolopirazinona util como un inhibidor de pde1 humana PE20190452A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662379372P 2016-08-25 2016-08-25

Publications (1)

Publication Number Publication Date
PE20190452A1 true PE20190452A1 (es) 2019-03-29

Family

ID=59762063

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000371A PE20190452A1 (es) 2016-08-25 2017-08-18 Derivado de triazolopirazinona util como un inhibidor de pde1 humana

Country Status (37)

Country Link
US (1) US10138244B2 (es)
EP (1) EP3504208B1 (es)
JP (1) JP6633246B2 (es)
KR (1) KR20190028544A (es)
CN (1) CN109641902B (es)
AR (1) AR109328A1 (es)
AU (1) AU2017317111A1 (es)
BR (1) BR112019000988A2 (es)
CA (1) CA3034828A1 (es)
CL (1) CL2019000487A1 (es)
CO (1) CO2019001644A2 (es)
CR (1) CR20190078A (es)
CY (1) CY1123406T1 (es)
DK (1) DK3504208T3 (es)
DO (1) DOP2019000021A (es)
EA (1) EA201990313A1 (es)
EC (1) ECSP19013196A (es)
ES (1) ES2800433T3 (es)
HR (1) HRP20201187T1 (es)
HU (1) HUE050419T2 (es)
JO (1) JOP20170164A1 (es)
LT (1) LT3504208T (es)
MA (1) MA46039B1 (es)
MD (1) MD3504208T2 (es)
ME (1) ME03791B (es)
MX (1) MX2019002065A (es)
PE (1) PE20190452A1 (es)
PH (1) PH12019500370A1 (es)
PL (1) PL3504208T3 (es)
PT (1) PT3504208T (es)
RS (1) RS60442B1 (es)
SG (1) SG11201901311WA (es)
SI (1) SI3504208T1 (es)
SV (1) SV2019005838A (es)
TN (1) TN2019000038A1 (es)
TW (1) TWI651323B (es)
WO (1) WO2018039051A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR112457A1 (es) * 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
AR112346A1 (es) 2017-08-10 2019-10-16 Lilly Co Eli Derivados de [1,2,4]triazolo
US11453673B2 (en) 2018-02-06 2022-09-27 Eli Lilly And Company Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors
WO2021035157A1 (en) * 2019-08-22 2021-02-25 Intra-Cellular Therapies, Inc. Organic compounds
WO2025059641A1 (en) 2023-09-14 2025-03-20 Eli Lilly And Company Pde1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4354027A (en) 1980-05-19 1982-10-12 Usv Pharmaceutical Corporation Triazoloquinoxalin-4-ones
AU2007332440B2 (en) * 2006-12-13 2013-05-16 Aska Pharmaceutical Co., Ltd. Quinoxaline derivative
WO2008103357A1 (en) 2007-02-21 2008-08-28 E. I. Du Pont De Nemours And Company Fungicidal tricyclic 1,2,4-triazoles
PH12013500401A1 (en) 2010-09-07 2013-03-25 Astellas Pharma Inc Quinoxaline compound
ES2904267T3 (es) * 2012-06-18 2022-04-04 Dart Neuroscience Llc Composiciones farmacéuticas de derivados de 6H-pirido[3.2-e][1.2.4]triazolo[1,5-c]pirimidina-5-ona y[1.2.4]triazolo[1,5-c]pteridina-5(6H)-ona como inhibidores de PDE1 para el tratamiento, por ejemplo, de trastornosneurológicos
US9938284B2 (en) * 2014-08-07 2018-04-10 Intra-Cellular Therapies, Inc. Organic compounds
US20160083400A1 (en) * 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) * 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
AR107456A1 (es) 2016-02-12 2018-05-02 Lilly Co Eli Inhibidor de pde1

Also Published As

Publication number Publication date
ME03791B (me) 2021-04-20
DK3504208T3 (da) 2020-07-27
KR20190028544A (ko) 2019-03-18
ES2800433T3 (es) 2020-12-30
PT3504208T (pt) 2020-08-31
CL2019000487A1 (es) 2019-07-12
CO2019001644A2 (es) 2019-05-21
PH12019500370A1 (en) 2019-10-21
SV2019005838A (es) 2019-04-04
RS60442B1 (sr) 2020-07-31
US10138244B2 (en) 2018-11-27
MD3504208T2 (ro) 2020-08-31
CR20190078A (es) 2019-04-05
WO2018039051A1 (en) 2018-03-01
JP6633246B2 (ja) 2020-01-22
CN109641902B (zh) 2021-06-08
EP3504208B1 (en) 2020-06-10
JOP20170164A1 (ar) 2019-01-30
JP2019526567A (ja) 2019-09-19
MX2019002065A (es) 2019-06-03
TWI651323B (zh) 2019-02-21
TW201819379A (zh) 2018-06-01
DOP2019000021A (es) 2019-02-28
LT3504208T (lt) 2020-08-10
HUE050419T2 (hu) 2020-12-28
ECSP19013196A (es) 2019-03-29
CN109641902A (zh) 2019-04-16
PL3504208T3 (pl) 2020-11-16
AU2017317111A1 (en) 2019-01-31
MA46039B1 (fr) 2020-09-30
CY1123406T1 (el) 2021-12-31
CA3034828A1 (en) 2018-03-01
EP3504208A1 (en) 2019-07-03
HRP20201187T1 (hr) 2020-11-13
SG11201901311WA (en) 2019-03-28
SI3504208T1 (sl) 2020-08-31
AR109328A1 (es) 2018-11-21
EA201990313A1 (ru) 2019-07-31
TN2019000038A1 (en) 2020-07-15
BR112019000988A2 (pt) 2019-05-14
US20180057494A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
CL2019002204A1 (es) Compuestos inhibidores del vih.
CL2023001369A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
UY35263A (es) Compuestos terapéuticos
PE20190452A1 (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana
SG10201811384TA (en) Mnk inhibitors and methods related thereto
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
EA201792421A1 (ru) Амидозамещенные производные циклогексана
EA201591457A8 (ru) Терапевтические соединения
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
MX2016013801A (es) Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes.
MX377202B (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
MX391440B (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
NZ721645A (en) Compounds for use as gpr120 agonists
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX383975B (es) Derivado de anillo fusionado como inhibidor del receptor a2a
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
BR112020026014A8 (pt) Derivado de lactama condensado